Cellular immunotherapies for cancer-Reference-Cited by-同舟云学术

Cellular immunotherapies for cancer

Published:2017-05-02 Issue:5 Volume:6 Page:e1306619
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Berraondo Pedro¹²³^ORCID,Labiano Sara¹²,Minute Luna¹²,Etxeberria Iñaki¹²,Vasquez Marcos¹²,Sanchez-Arraez Alvaro¹²,Teijeira Alvaro¹²³,Melero Ignacio¹²³⁴^ORCID

Affiliation:

1. Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain

2. Navarra Institute for Health Research (IDISNA), Pamplona, Spain

3. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain

4. Servicio de Inmunología e Inmunoterapia, Clínica Universidad de Navarra, Pamplona, Spain

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2017.1306619

Reference32 articles.

1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

2. Nivolumab in Previously Untreated Melanoma withoutBRAFMutation

3. Nivolumab plus Ipilimumab in Advanced Melanoma

4. An initial and rapid step of lytic granule secretion precedes microtubule organizing center polarization at the cytotoxic T lymphocyte/target cell synapse

5. Individual Human Cytotoxic T Lymphocytes Exhibit Intraclonal Heterogeneity during Sustained Killing

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic role of long non-coding RNA USP30-AS1 in ovarian cancer: insights into immune cell infiltration in the tumor microenvironment;Aging;2023-12-04

2. Porous Framework Materials for Bioimaging and Cancer Therapy;Molecules;2023-01-31

3. Expression and prognosis analyses of the fibronectin type-III domain-containing (FNDC) protein family in human cancers: A Review;Medicine;2022-12-09

4. Glycosylated 4‐methylumbelliferone as a targeted therapy for hepatocellular carcinoma;Liver International;2021-12-10

5. Selective therapeutic benefit of X-rays and inhibitors of EGFR, PI3K/mTOR, and Bcl-2 in breast, lung, and cervical cancer cells;European Journal of Pharmacology;2021-12